ABSTRACT
INTRODUCTION Within the last decade, thoracic endovascular aortic repair (TEVAR) has been increasingly performed on patients with more advanced age as well as on thoracic aortic pathology being located within the aortic arch as supra-aortic transpositions have become an established, safe, and reproducible procedure (1-7). Indications for treatment contain dilatative as well as obliterative pathology, primarily aneurysms, being followed by a steadily increasing number of penetrating atherosclerotic ulcers (8). Furthermore, TEVAR has become the modality of choice in patients with complicated type B dissections (9,10). By a better understanding of the mechanisms of intramural hematoma (IMH), TEVAR is also applied in patients presenting with IMH of the entire thoracic aorta (11).
